Published in Vaccine Weekly, November 29th, 2006
In addition, ongoing studies of GelVac formulations incorporating influenza antigens exhibited the potential for long-term stability during storage at room temperature.
In a presentation entitled "A Stable Dry Powder Vaccine Formulation (GelVac) for Nasal Delivery" at the 2006 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Antonio, Texas, Babu M. Medi, PhD, pharmaceutical scientist at DelSite Biotechnologies,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-11-29)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.